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The incidence rate of malignant melanoma is increasing in Norwegian 
population as well as worldwide. Malignant melanoma is one of the most aggressive 
human cancers showing exceptional abilities to metastasize and develop resistance 
to therapy. Currently there are no effective treatments against metastatic melanoma. 
Traditionally, melanoma aggressiveness was linked to intrinsic properties of the 
malignant cells themselves. However, it is becoming apparent now that the tumor 
microenvironment (TME) – non-malignant (stroma) cells, soluble molecules and 
extracellular matrix components – can play an important role in modulating 
metastatic properties and sensitivity to drugs in cancer cells.  
In the present work we investigated how various TME factors like extracellular 
matrix components (fibronectin and laminin) and soluble factors released from mice 
organs – common sites of melanoma metastasis - affected melanoma cells, 
specifically their metastasis-associated properties like growth/proliferation and 
sensitivity to the experimental dug Elesclomol. The study was based on three-
dimensional (3D) in vitro cultures, where melanoma cells were grown in a Collagen 
or Matrigel matrix in the presence of investigated factors of TME. Two melanoma 
cells lines, Melmet 1 and Melmet 5 derived from the metastatic melanoma patents 
with different clinical indications were employed.  
It was observed that fibronectin and laminin did not have a notable effect on 
cell growth or viability. However, the soluble factors from the organs showed a slight 
stimulating effect on cell growth and a notable effect on cell morphology and growth 
pattern. The latter was especially pronounced for the bone marrow-derived factors. 
Comparison of the sensitivity of Melmet cells to Elesclomol in 3D versus 2D revealed 
that 3D cultures were less sensitive to the drug, and that Melmet 5 was less sensitive 
compared to Melmet 1. The sensitivity was not modulated by the soluble factors 
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Melmet 5 Melanoma 5 cell line                        
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MITF Microphthalmia-assosiated transcription 
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TGFβ Tumor Growth Factor β 
MMP Matrix Metalloproteinases 
TAF Tumor-assosiated fibroblasts 
Treg T regulatory cell 
VEGF Vascular endothelial growth factor 
BMDC Bone marrow-derived cells 
GIST Gastrointestinal stromal tumor 
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1.1 Melanoma: clinical aspects and biology 
 
 
Melanoma is among the cancers that are rapidly increasing in Norway as well 
as worldwide. There are registered about 1300 new cases of malignant melanoma of 
the skin in Norway in 2008, and this is the second most common cancer (11%) after 
testicular cancer (20%) in men aged 25-49 years. In young women aged 15-24 
years, melanoma is the second most common cancer (13%), after tumors of the 
central nervous system (21%) (Cancer in Norway 2008, Bray F.,Grimsrud 
T.,Haldorsen T., Cancer Registry of Norway 2009). Malignant melanoma is the most 
dangerous form of skin cancer accounting for more than 70% of all skin cancer-
related deaths (Villanueva and Herlyn 2008). According to the World Health 
Organization, the incidence of malignant melanoma is increasing faster than any 
other cancer in the world, especially in women younger than 40 years and in men 
older than 40 (Erickson and Driscoll). So it seems that melanoma mostly is affecting 
young and middle-aged people, unlike most other solid tumors, which mainly affect 
older adults. There exist several risk factors for the development of cutaneous 
malignant melanoma (see Table 1), but accumulating evidence suggests that 
exposure to sunlight and other sources of ultraviolet irradiation is the critical one 
(Gallagher, Spinelli et al. 2005). 
 
 
Table1. Risk factors which increase the risk for development of cutaneous  
malignant melanoma. 
Risk factors for cutaneous malignant melanoma 
History of melanoma or nonmelanoma skin cancer 
Family history of cutaneous malignant melanoma 
Atypical nevi or numerous nevi 
History of severe (blistering) sunburns or intense intermittent sun exposures 
Light skin, blond hair 
Giant melanocytic nevus 
 
 
Patients with early stages of melanoma (when lesions are less than 1mm 
thick without metastases) have a good prognosis, because a lesion can be removed 
by surgery, which is currently the only curative treatment. However, melanoma can 
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progress rapidly from a surgically curable lesion to an aggressive metastatic disease 
(Figure 1), able to establish metastases in multiple organs and showing poor 
response to current therapies, resulting in high mortality. Thus, the prognosis for 
melanoma patients with distant metastases is very bad: a median survival is of only 




Figure 1. Melanoma lesion. Melanoma can progress rapidly from a surgically curable lesion 




Melanoma arises from malignant transformation of melanocytes which are 
pigmented cells found predominantly in the skin and eyes (Gray-Schopfer, Wellbrock 
et al. 2007). The progression from normal melanocytes to metastatic disease is a 
multistep process (see Figure 2). It starts with structurally normal melanocytes as 
benign nevi and develops to dysplastic nevi with structural atypia. These two phases 
can be identified as primary events in melanocytic abnormal proliferation. Further it is 
followed by a radial growth phase (a primary tumor), vertical growth phase which has 
a potential for metastasis and ends with metastatic melanoma. A primary tumor 
grows horizontally through the epidermis; over time, a vertical growth phase 
component intervenes and melanoma increases its thickness, invades the dermis 
and disseminate to regional lymph nodes and distant organs, like brain, lungs, liver 
(Miller and Mihm 2006; Gaggioli and Sahai 2007).  
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Figure 2. Melanoma progression. Mutations in BRAF and NRAS initiate the abnormal 
activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which disrupts 
growth control in normal melanocytes in benign nevi. Inactivation of cyclin dependent kinase 
inhibitor 2A (CDKN2A) and phosphatase and tensin homologue (PTEN) pathway, which 
encodes tumor-suppressor genes, triggers development of cytologic atypia in dysplastic nevi. 
Further progression of melanoma is associated with the overexpression of the CD1 oncogene 
and the decreased expression of melastatin 1(TRPMI1) and other genes underlying melanin 
synthesis, which is regulated by microphthalmia-assosiated transcription factor (MITF). The 
next step in development, i.e. progression from a vertical-growth phase to metastatic 
melanoma.This process is associated with alterations in control of cell adhesion: loss of E-
cadherin and expression αVβ3 integrin, which induces expression of matrix metalloproteinase 
2 - an upregulated enzyme in invasive melanoma that promotes melanoma cell dissemination 
via degradation of the collagen in basement membrane. In addition, αVβ3 integrin increases 
expression of the prosurvival genes and stimulates the motility of melanoma cells through the 
reorganization of melanoma cytoskeleton leading to formation of metastasis (adapted from 




To understand the onset of malignancy substantial advances have been 
made on genetic level. The genetic changes, associated with biology underlying the 
initiation and progression of melanoma, include: (a) mutation of BRAF and NRAS 
and consequently up-regulation of the RAS/RAF/MEK/ERK pathways; (b) mutation in 
PI(3)Ks pathway and loss of PTEN function; (c) down-regulation of the 
retinoblastoma protein (RB) by increased cyclin D1 or CDK4 activity; (d) inactivation 
of the CDKN2A p16 suppressor of CDK4; (e) intermediate levels of MITF, which 
regulate the melanogenesis and survival (see Figure 2) (Miller and Mihm 2006; 
Gray-Schopfer, Wellbrock et al. 2007). 
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Invasion and spread of melanoma are associated with alterations in cell 
adhesion. Integrins are main receptors for cell adhesion to extracellular matrix 
proteins, which regulates a variety of cellular processes, including proliferation and 
cell survival (Hynes 2002). The main ECM components that integrins bind to are 
collagen, laminin and fibronectin. The integrin alphaVbeta3 dimer appears to be 
particularly important for the invasive potential of melanoma cells (Figure 2) (Dang, 
Bamburg et al. 2006).  
Other adhesion molecules, cadherins are part of larger protein complexes 
that link cell adhesion to control of cell morphology, motility, and intracellular 
signalling events. The biology of normal melanocytes is tightly controlled by 
keratinocytes that interact via E-cadherin.  Loss of E-cadherin and gain of N-cadherin 
is a characteristic event associated with the disease progression from a vertical 
growth phase to metastasis (Figure 2). Increased levels of N-cadherin enable 
melanoma cells to interact instead with fibroblasts and vascular endothelial cells in 
the dermis (Smalley, Brafford et al. 2005). Thus, cells lacking E-cadherin and 
expressing N-cadherin are able to survive and as a result invade distant tissues 
effectively (Hsu, Meier et al. 2000).  
Moreover, cell invasion is mediated by proteinases such as matrix 
metalloproteinases (MMPs). MMPs belong to a family of calcium- and zinc-
dependent endopeptidase that can degrade and digest a wide range of interstitial 
and basement membrane proteins in the extracellular matrix. MMPs, particularly 
MMP-2 and MMP-9 are implicated in tumor cell invasion and represent an important 
stage of tumor progression by its expression in invasive melanoma (Simonetti, 
Lucarini et al. 2002; Schnaeker, Ossig et al. 2004).  
 
 
1.2 Tumor microenvironment (TME) and its role in metastasis 
 
One of the main hallmarks of malignant melanoma is its exceptionally high 
ability for metastasis. Metastasis is a very complex process.  First, tumor cells have 
to leave the primary tumor by loosening cell-cell contacts and adhering to and 
degrading extracellular matrix (ECM). Then the tumor cells migrate through tumor 
endothelial basement membrane and through or between endothelial cells to enter 
the blood or lymphatics- intravasation process. Once in circulation, the tumor cells 
have to survive i.e. avoid immune recognition and resist the process of programmed 
cell death. Surviving cells can become arrested in the capillaries of distant organs, 
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where they must adhere to the endothelial basement membrane and extravasate into 
the tissue. Then, the metastasizing tumor cells have to survive the stresses of a new 
microenvironment characteristic for this organ, proliferate there, and successfully 
grow into a measurable metastatic lesion (see Figure 3) This distant site progresses 
can also develop through single cells, which might remain dormant for years (Steeg 




Figure 3. A schematic presentation of metastatic process. A- represents tumor growth, b- 
invasion, which requires reversible changes in cell–cell and cell–extracellular-matrix 
adherence, c- cells can metastasize via lymphatic or d- directly enter the circulation, e- 
survival and arrest of tumor cells and extravasation occurs next, f- establishment of the 
microenvironment through metastasizing cells or dormant cells, g- tumor are now 




Earlier it was though that metastasizing cancer cells themselves 
independently could overcome all these obstacles along the metastatic cascade. 
However, now it is becoming more and more clear that tumor microenvironment 
(TME) plays a very important role in assisting tumor cells in metastasis.  Interestingly, 
the association between TME and metastasis as a “Seed and soil” hypothesis was 
first time suggested by Stephen Paget over a century ago in 1889 to explain organ 
preferred metastasis. This hypothesis suggested that tumor cells (seed) can colonize 
Primary tumor Invasion 











only these distant organs (soil) where there is a favorable environment for tumor 
growth. Stephen Paget concluded that metastases resulted only when the seed and 
soil were compatible (Paget 1989). However, only recently Pagets ideas received a 
lot of attention, and TME in cancer progression, metastasis and drug-response 
became a very actively investigated topic.  
Tumor microenvironment generally consists of extracellular matrix (ECM) and 
different type of non-malignant cells like fibroblasts, endothelial cell and bone 
marrow-derived cells (BMDC), which include myeloid precursors, macrophages and 
other immune cells. All these cells  can contribute to tumor progression and 
metastasis by releasing a variety of inflammatory-, growth- and survival-factors 
(chemokines, cytokines, growth factors (GFs)), extracellular proteases and 
proangiogenic factors, which altogether also belong to TME (Baglole, Ray et al. 
2006; Mantovani, Allavena et al. 2008). 
Bone-marrow derived cells (BMDC) are particularly interesting cell type lately 
discovered to be strongly involved in metastasis via the formation of a “pre-metastatic 
niche”. Thus, it has been suggested that primary tumor directs early changes within 
sites of future metastasis through the recruitment of a certain type of BMDCs to 
tumor-specific pre-metastatic sites. This leads to the changes preparing the tissue to 
receive the disseminating tumor cells (Kaplan, Riba et al. 2005; Kaplan, Psaila et al. 
2006; Joyce and Pollard 2009). The changes reported to be associated with a ”pre-
metastatic niche” include: 1) modulation of ECM like enhanced production of 
fibronectin (Kaplan, Riba et al. 2005); and 2) generation of an inflammatory state by 
inducing pro-inflammatory cytokines (Yan, Pickup et al.). 
Recently inflammation has been suggested to represent one of the hallmarks 
of cancer (Hanahan and Weinberg). The association between inflammation and 
promotion of cancer was first observed in 1863 by Rudolf Virchow (Balkwill and 
Mantovani 2001). Recent studies support the notion that cancer-associated 
inflammation promotes tumor growth and progression (Coussens and Werb 2002; 
Balkwill, Charles et al. 2005). Thus, inflammation can supply bioactive molecules to 
the microenvironment, including growth factors that sustain proliferation, survival 
factors that limit cancer cell death, proangiogenic factors, ECM-modifying enzymes 




Figure 4. Impact of inflammation-related microenvironment factors on progression of 
epithelial cancers. Stroma cells, mainly fibroblasts and immune cells, are separated from the 
epithelium by the basement membrane. In association with inflammation, fibroblasts become 
activated, proliferate and differentiate into tumor-associated fibroblasts (TAFs). TAFs, in turn, 
secrete immunoregulatory molecules such as TGF-β, Cox-2 and PGE2. Increased Cox-2 
expression is common in most cancers and PGE2 maintains tumorigenesis by immune 
suppression, angiogenesis and epithelial growth. Immune cells such as T lymphocytes 
(including T regulatory cells) and dendritic cells are recruited to the stromal compartment to 





Figure 4 illustrates the mechanism how the inflammation-related 
microenvironment factors could support cancer progression. Such mechanism has 
been suggested for epithelial cancers, which so far remains to be the best 
investigated cancer form with respect to the TME. However, other cancer forms can 
follow the similar mechanisms. Melanoma cells in generally express a variety of 
cytokines, chemokines and their receptors (Richmond, Yang et al. 2009). Growth 
factor TGFβ– is one of the most potent immunosuppressive cytokines. In cancer, 
together with IL-2, it targets and promotes differentiation of the regulatory T cells 
(Treg), a strongly immunosuppressive T cells found in melanoma and other tumors. 
This contributes to tumor escape from immune surveillance. In addition, TGFβ can 
promote tumor angiogenesis, invasion and metastasis by stimulating expression of 
various metastatic markers, including MMPs, VEGF and integrins (Li, Wan et al. 
2006; Padua and Massague 2009). 
 Inflammation 
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COX 2 is inducible enzyme of inflammatory reactions (see Figure 4). It 
catalyzes the production of prostaglandins (PGE) in inflammatory processes and is 
frequently expressed in malignant melanomas and may have a correlation with 
cancer progression (Denkert, Kobel et al. 2001; Meyer, Vogt et al. 2009).  
Besides various stroma cells and soluble factors facilitating metastasis, 
various components of the extracellular matrix - another constituent of TME - also 
can play a role in metastasis. Proteins such as collagen, laminin and fibronectin are 
the major structural components of ECM. Laminin is a main protein of basement 
membrane. Usually, melanoma cells have high affinity to exogenous laminin, which 
they have to degrade in order to cross basement membrane during metastatic 
dissemination (see Figure 1) (Terranova, Williams et al. 1984). Fibronectin has also 
been strongly linked to the metastasis process, since enhanced levels of fibronectin 
were observed in metastatic organs, particularly around the metastatic lesions. 
Interestingly, enhanced expression of fibronectin has been linked to the formation of 
a pre-metastatic niche, specifically in lungs, where fibronectin could further facilitate 
the development of a metastatic lesion as discussed above (Kaplan, Riba et al. 
2005). 
In summary, it appears that metastasis is governed on a systemic level i.e. 
involves various non-malignant (stroma) cells, soluble factors and ECM components. 
This research field is still at the very early phase, and the direct contribution of each 
element of TME in metastasis in various cancer forms, particularly in melanoma, 
remains to be elucidated. Eventually, this might uncover novel targets for therapy. It 
is proposed that targeting tumor cells together with the targeting of implicated TME 
factors can improve the efficiency of anticancer therapy.  
  
 
1.3 Melanoma therapy 
 
Melanoma is an extremely aggressive disease, and high resistance to therapy 
is one of the main hallmarks of metastatic melanoma. Generally, drug-resistance 
may be associated with communication between tumor cells and surrounding 
microenvironment (Meads, Gatenby et al. 2009). The pathways/oncogenes, 
microenvironmental factors and enzymes mentioned in the chapters above 
represents attractive potential targets and offer a novel approach for therapeutic 
strategies and treatment also in melanoma (see Table 2) (Gray-Schopfer, Wellbrock 
et al. 2007; Villanueva and Herlyn 2008). 
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Table 2. Single agents targeting different components of the melanoma tumor 
microenvironment in clinical trials (adapted from Villanueva and Herlyn, 2008). 
Target Compound Mechanism Phase Comments 
AG-013736 VEGFR and PDGFR 
inhibitor 
2 Starting dose 5 mg twice 
daily ± 20% according to 
toxicity 
ABT-510 Synthetic analogue 
of thrombospondin-1/ 
angiogenesis inhibitor 
2 100 mg twice daily in 
patients with metastatic 




inhibitor of VEGFR 
family 
2 May also inhibit Kit and 
(less potently) 




Fusion protein that 
binds VEGF-A and 
placental growth factor 
2 Effectively suppresses 
tumor growth and 
vascularization in vivo 
Bevacizumab Anti-VEGF humanized 
monoclonal antibody 
binds to VEGF and 
inhibits VEGF receptor 
binding 
1/2 Treatment with intravitreal 
bevacizumab for large 
uveal melanomas; efficacy 
of bevacizumab 
monotherapy being tested 






2 Proapoptotic in preclinical 
studies; blocks hypoxia-











2 Humanized monoclonal 
antibody potent in vivo 




αvβ3 and α5β1 
integrins 




cell–ECM interactions, and 
angiogenesis 
CNTO 95 αv integrins 1/2 Human monoclonal 
antibody; inhibits 
melanoma cell adhesion, 
migration, and invasion 
COL-3 (NSC-
683551) 
MMP-2 and MMP-9 1 Completed 
Marimastat MMP 2 Limited activity in 
melanoma; trials in 
Canada and Europe 
GC1008 Human anti-TGF- β 
monoclonal antibody 
1  
RAF-265 MAPK inactivation/ 
BRAF and VEGFR-2 
inhibitor 
1 Inhibits the RAF/MAPK 
pathway as well as VEGF 
























































including Kit, PDGFR, 
VEGFR 
2 FDA approved for GIST 




However, despite big efforts during the last decades testing various treatment 
strategies, none significantly prolonged patient survival. An alkylating agent 
dacarbazine (DTIC) has been most commonly used single agent in metastatic 
melanoma treatment. It was FDA-approved for malignant melanoma in 1976 and still 
remains the sole approved chemotherapeutic drug for this cancer type. 
Unfortunately, DTIC alone or in combination with other chemotherapeutic agents 
elicit durable response in very few patients (i.e. less than 25%) (see Table 2) 
(Jilaveanu, Aziz et al. 2009). 
 
 
Table 3. Respone rates of melanoma treatment with single chemotherapeutic agents 
(adapted from Jilaveanu, 2009). 
Agent Response rate, % 
Dacarbazine 7-25 
Temozolomide (TMZ) 21 




Vinflunine ditartrate 3 









Immunotherapy has also been investigated in metastatic melanoma. High 
dose of Interleukin-2 (IL-2), which plays a central role in immunoregulatory process 
by cytotoxic activity and stimulation of natural killer cells, is another FDA-approved 
agent (in 1998) for advanced melanoma. Different regimes and schedules have been 
tried without association with better survival, but rather with even higher toxicity than 
with chemotherapeutics (Agarwala 2009). 
Lack of efficient drugs against malignant melanoma stimulated an intensive 
research on new therapeutic options. Recently, a novel strategy for apoptosis 
stimulation, based on the induction of reactive oxygen species (ROS), has emerged. 
A small molecular drug named Elesclomol (Synta Pharmaceutical) is a ROS-inducing 
agent, which leads to apoptosis directly, or sensitizes cells to other agents. 
Generally, melanomas have high levels of ROS as compared to normal cells, and 
elevation of ROS beyond the “threshold” level induces cell death. In a recent Phase II 
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trial in metastatic melanoma Elesclomol demonstrated an improved patient survival 
(Kirshner, He et al. 2008; Tuma 2008).  
Lately, a new promising drug PLX4032, a small molecular inhibitor of mutated 
BRAF (BRAFV600E, a mutation observed in 40-60% melanomas) entered clinical trials. 
The first results were dramatic: the majority of the patients treated with PLX4032 
exhibited complete or partial tumor regression. Unfortunately, the drug stopped 
working after ~7months, and at present a lot of research focuses on understanding 
the molecular mechanism of such resistance and the ways to overcome it (Ledford; 
Vultur, Villanueva et al.). Likely, PLX4032 has to be combined with other drugs to 
create a more potent cocktail against malignant melanoma.  
 
 
1.4 Three-dimensional in vitro cultures – an in vitro model to study 
cancer properties in the setting of TME  
 
As discussed above, TME components play an important role in cancer cell 
proliferation, invasion and survival. Therefore, there is a high need for models like 
cell culture systems in vitro, that would allow studying cancer cell behavior in the 
presence of TME components.  One of such models is three-dimensional (3D) cell 
cultures, where the cells are embedded in a matrix of e.g. a collagen – the main 
component of ECM. Culturing cells within three-dimensional matrices is not a novel 
idea. Already in 1972, a model system was described for fibroblastic cells in the body 
using collagen I matrices polymerized in vitro to form a three-dimensional fibrous 
network. These three-dimensional collagen gels induced morphological changes in 
fibroblasts that partially mimicked connective tissue cells in vivo (Elsdale and Bard 
1972). 
Lately, it is becoming recognized that 3D matrix-based cell cultures are 
superior in vitro models compared to traditional 2D monolayer cultures grown on a 
plastic surface. There are some limitations to the 2D models that are apparent when 
compared to cells grown in a 3D matrix. For example, 3D models incorporate TME 
components like ECM and therefore, mimic the situation in vivo more closely. 
Important cell-cell or cell-ECM contacts, which are lost in ”flat” 2D monolayers, can 
be restored in matrix-based 3D systems. Having in mind that cell-cell or cell-matrix 
interactions are important in regulating cell survival and invasion, 3D models are 
highly relevant systems for in vitro studies of tumor cell growth, migration, invasion 
and drug response.  
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Interestingly, it has been shown previously that tumor cells responsiveness to 
drugs in 2D and 3D systems can differ tremendously, and that microenvironment 
components like ECM present in 3D cultures can influence drug-response (Smalley, 
Lioni et al. 2006; Serebriiskii, Castello-Cros et al. 2008). Furthermore, it has been 
shown that drug efficiency observed in vivo is closer to the efficiency seen in 3D than 
in 2D in vitro systems. Generally it has been observed that the sensitivity to drugs is 
lower in vivo and in 3D compared to 2D. This might explain an often seen situation: 
drugs that show high efficiency in 2D fail to show the same efficiency in vivo or in the 
clinic. Therefore, lately use of 3D systems for testing new therapeutic approaches 
gets in focus.  
3D cell cultures are usually based on matrixes consisting of collagen or 
Matrigel that were also used in the present work. Collagen I is a matrix component 
highly relevant for melanomas: it is present in the skin where a primary tumor 
develops, while Matrigel is rich in laminin – the main component of the basement 
membrane that melanoma cells have to cross during dissemination from a primary 
tumor. Besides, 3D cultures can be supplemented with additional factors of TME, like 
various soluble factors or stroma cells. Such systems allow investigation of cancer 
cell behaviour in vitro in 3D and in the presence of relevant TME components 
(Studebaker, Storci et al. 2008). 
Growing interest in the role of TME in cancer also boosted the interest in 
more relevant in vitro models like 3D systems. Therefore, the present project was 
built on 3D cell cultures to investigate how various components of TME affect 















The aim of the study 
 
The present project focuses on metastatic melanoma and how its aggressive 
properties are influenced by the factors of tumor microenvironment (TME). The 
overall aim is to identify how various TME-associated factors affect melanoma cell 
growth and response to therapy in vitro. Importantly, the study is performed by 
employing three-dimensional (3D) matrix-based cell cultures that allow partial 
recapitulation of TME and therefore mimic the in vivo situation more closely.  
The specific aims were: 
1) To elucidate adhesion abilities of melanoma cell to various components of 
extracellular matrix (ECM) and to reveal how selected ECM proteins affect 
melanoma cell growth in 3D.  
2) To evaluate the effect of soluble factors released from different organs – 
common sites of melanoma metastasis – on tumor cell growth and drug-
response. 
3) To compare melanoma cell sensitivity to the drug Elesclomol in 3D versus 2D 
cultures and to evaluate whether/how melanoma sensitivity to Elesclomol is 






















































2. Materials and methods 
 
2.1 Cell lines: Melmet 1 and Melmet 5 
 
Metastatic melanoma cell lines, Melmet 1 and Melmet 5, were established 
from the biopsies of metastatic melanoma patients (see Table 4 for more 
information) at the department of Tumor Biology, The Norwegian Radiumhospital as 
described previously (Prasmickaite, Engesaeter et al.). Briefly, melanoma cells were 
isolated from the mechanically disintegrated biopsies by the help of immunomagnetic 
beads conjugated to the melanoma-specific antibody. The isolated tumor cells were 
cultured as two-dimensional (2D) monolayers in RPMI medium supplemented with 
10% Fetal Bovine Serum (FBS) and 5% L-Glutamin as described further in general 
cell work. 
 
Table 4. Background information about Melanoma cell lines. 
 Melmet 1 Melmet 5 
Source Female /36 years  Male /56 years 
Tissue (sites of biopsies) Subcutaneous Lymph node 
Distant metastasis Brain, lung, breast, skin Brain, lung, liver, abdomen 
Tumorigenicity in mice 
(subcutaneous growth) 
Yes Yes 
Metastatic ability in mice Yes Yes 
In vitro response to the 
approved drug DTIC in 2D 
Poor Poor 
 
Both cell lines easily adhere to a bottom of a culture flask and form a 
monolayer, but Melmet 1 grow slower than Melmet 5. The morphology of Melmet 
cells grown in 2D is shown in Figure 5. 
 
 





In addition, red colour-labelled Melmet cells lines, which stably express a 
fluorescent protein DsRed (further referred as DSRed Melmet 1 and DSRed Melmet 
5) were used in some of the experiments described below. Due to the DsRed label, 
these cells can be tracked by a fluorescent microscopy or analysed by a plate reader 
measuring the fluorescence signal (see Figure 5 C). 
Both Melmet 1 and Melmet 5 cells show high abilities to metastasize and 
resist therapies and, therefore, are representative and useful models for the studies 
on malignant melanoma. 
 
 
2.2 General cell work: cell culturing in 2D 
 
Routinely, melanoma cells were grown in cell culture flasks in RPMI 1640 
medium supplemented with FBS (10%) and L-Glutamine (5%) (further referred as 
“RPMI++”) in an incubator with 5% CO2 at 37ºC. The confluence of the cell 
monolayers was checked daily by an inverse microscope (Olympus CKX41). Cells 
were subcultured and the medium was replaced 2-3 times weekly. All procedures 
were performed under sterile conditions. Materials and instruments which were used 
for cell culturing are listed in Table 2. 
For cell subculturing the growth medium was removed from the flask and the 
cell monolayer was first washed once with 2 ml EDTA. Then a new 1 ml of EDTA 
was added and incubated for about 2-3 minutes at room temperature (or in an 
incubator at 37ºC to speed up cell detachment), and the cell flasks were roughly 
shaked to facilitate cell detachment. When all the cells were detached, 2-3ml of new 
medium was added directly to the flask, and a homogenous cell suspension was 
prepared. The desired amount of this cell suspension was transferred to a new 
culture flask and diluted with fresh RPMI++ (the total volume of the medium culture 
flask was 10ml).  
For applications where the cell concentration had to be determined, the 
detached cells in EDTA suspension were transferred to a new tube. The remaining 
cells were collected into 2-3ml new medium and transferred to the same tube. After 
centrifugation at 1200 rpm for 5 minutes, the supernatant was removed and the cell 
pellet was resuspended in fresh RPMI++ pippeting up and down to make a 
homogenous cell suspension. For cells counting, 10μl of the cell suspension was 
mixed with 10μl of trypan blue (which stains dead cells and, therefore, allows 
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exclusion of dead cells during counting), and 10μl of the mix was added directly to 




Figure 6. Cell counting method. Viable cells are counted in some squares of the Burker 
chamber. Then average count per square is multiplied by dilution factor and 10^4.  
 
 
Further, viable cells were counted in some squares of the chamber (see 
Figure 6) so the average count per square could be determined. To get the finally 
cells number in 1 ml of cell suspension, average count per square was multiplied by 
the dilution factor and by factor 104. 
All reagents, materials and instruments used in “General cell work: cell 
culturing in 2D” are listed in Table 5. 
 
Table 5. Materials and methods used in general cell work. 
Materials/instruments: Company: 
RPMI 1640 Lonza, Belgium 
Glutamine BibkoBRL, UK 
Fetal Bovine Serum (FBS) PAA, Austria 
Cell growth flasks with filter-caps NUNC
TM
, Denmark 
EDTA, Versene Lonza, Belgium 
2, 5, 10, 25 ml pipettes  Sarstedt, Numbrecht 
15 and 50 ml tubes Sarstedt, Numbrecht 
Filter tips Molecular Bio Produkts® 






Square view in microscope 
cells/ml =  
average count per 
square  
× dilution factor  
× 104 
Bürker counting chamber 
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2.3 Cells adhesion to extracellular matrix (ECM) proteins 
 
Cell adhesion to various proteins of ECM was evaluated by employing ECM 
Cell Adhesion Array Kit (CHEMICON®) according to the manufacture’s protocol. 
Briefly description of the procedure is as follows: A single cell suspension with a cell 
density of 2x106 cells per ml was prepared in advance. The kit-strips consisting of 
wells coated with a specific protein of ECM were rehydrated with PBS for 10 minutes. 
PBS was removed by turning over the strips and gently tapping 100µL of the 
prepared cell suspension was added to each well (i.e. 200x103 cells/well). Following 
the incubation for 2 hours at 37º C in a CO2 incubator, the media was removed and 
the wells were gently washed (2-3 times) with the Assay buffer. After washing, the 
Cell Stain Solution was added to each well and incubated for 5 minutes at room 
temperature, removed and gently washed for 3-5 times with the deionized water. The 
wells were left to air dry for a few minutes. The Extraction Buffer was added to each 
well and absorbance was monitored at 540 nm on a Walac plate reader. “Cell Stain 
Solution” stains the adhered cells, therefore, the wells with many attached cells are 
strongly stained and lead to high absorbance. In this way, the absorbance intensity 
allows identification of ECM proteins that melanoma cells adhere to.  
All reagents and materials used are listed in Table 6. 
 
Table 6. Materials and instruments needed for performance of the ECM kit. 
Materials/instruments: Company: 
ECM Cell Adhesion Array Kit  
(Colorimetric) Cat. No. ECM540 96 wells 
CHEMICON® International 
PBS Lonza, Belgium 
dH2O - 














2.4 Cell culturing in 3D 
 
 




Figure 7. 3D systems in vitro (1 single well). Melanoma cells are embedded within collagen 
matrix. Such systems can be supplemented with investigating factors embedded with cells in 
2nd layer or dissolved in the 3rd soluble layer.  
 
 
 3D cell cultures consist of three layers (see Figure 7): a 1st collagen layer, a 
2nd collagen layer with embedded cells and a 3rd top layer - growth medium, which 
can be supplemented with various soluble factors or investigated drugs. The 




Table 7. Preparation of 3D collagen-based cell cultures in 96-well plates (the indicated 
amounts are needed for 1 well). 
                            collagen final concentration 2.5 mg/ml 
  1st layer 
2nd layer with 





4xDMEM++ 10µl 10µl 
collagen I (stock 
5mg/ml) 25µl 25µl 
NaOH 0.025N 1µl 1µl 
H2O 4µl 4µl 
1x DMEM++  10µl - 

















 Collagen matrix 







 +/- factor X: 
•  FBS 
•  Elesclomol 





Basic protocol for preparation of 3D collagen-based cell cultures:  
Collagen I stock solution (5 mg/ml) was diluted with 4xDMEM supplemented 
with glutamine, antibiotics penicillin and streptomycin (further referred as 
“DMEM++”), H2O and NaOH (to adjust the final pH of the solution to 7, 4) as 
indicated in Table 7. All the ingredients and the tubes were kept on ice while mixing 
to avoid undesirable polymerization of the collagen. The culture plates were also pre-
chilled on ice before application of the 1st collagen layer.  
For the 1st layer, 50µl prepared as indicated in Table 7 were applied into each 
well. Air-bobbles, if they were formed, were removed by the help of a needle. After 
application of the 1st layer, the plate was transferred to room temperature for at least 
30 minute to allow polymerization of collagen. After polymerization, 50μl of the 2nd 
layer was added, which was prepared similarly to the 1st layer except that it was 
supplemented with desired amount of melanoma cells resuspended in 10μl 1x 
DMEM++ (see Table 7). Paralelly, “blank” wells lacking tumour cells in the 2nd layer 
were prepared by adding 50μl collagen solution on top of the polymerized 1st layer; 
“blanc” wells were used to measure a background signal (for the collagen and the 
investigating factors in 3rd top layer) which was substracted from a cell-mediated 
signal during final calculations (see chapter below). Subsequently, the plate was put 
into CO2 incubator at 37°C for at least 30 minutes to allow collagen polymerization.  
Finally, the polymerized gel was overlaid with 100µl of the 3rd top layer 
consisting of growth medium with or without investigated factor X. 1xDMEM medium 
supplemented with glutamine and penicillin/streptomycin was usually used as a 
“basic” growth medium, which could be further supplemented with FBS (further 
referred as “DMEM+2% FBS”), and/or a factor X e.g. investigated drugs or soluble 
molecules provided by conditioned media (see below).  Eventually the plate was put 
into CO2
 
incubator at 37°C and incubated for 1 to 5 days before the analysis. 
Samples were inspected visually every day by an inverse microscope (Olympus 
IX81). Besides, the plates were analyzed by a plate reader along the experiment or 
at the end of it.  






Table 8. Materials and instruments used in preparation of 3D collagen models. 
Materials/Instruments: Company: 
96 well black walled-clear bottom plate Greiner bio-one, Germany 
4× DMEM Sigma Aldrich, Switzerland  
1× DMEM Sigma Aldrich, Switzerland  
Phosphate Buffered Saline (PBS)  Lonza, Belgium  
Sterile dH2O  - 
15, 50 ml tubes  Sarstedt, Nümbrecht 
Eppendorf tubes  Trefflab, Switzerland 
Inverse microscope Olympus IX81  Olympus, Norway  
Bovine Collagen I Gibco ® 
Synergy2 plate reader BioTek, Norway  
Walac plate reader KSH-Productor Oy, Finland 
 






Matrigel 3D cultures consisted of 3 layers as indicated in Figure 8.  
Briefly, for the 1st layer, 50µl of Matrigel were applied directly into each well. 
Then, the plate, which was pre-chilled on ice before application of the 1st layer, was 
transferred to room temperature for at least 15min to allow polymerization of Matrigel. 
Bottle with Matrigel was also kept on ice during the application.  
The desired amount of melanoma cells suspension was centrifuged at 1200 
rpm for 5 minutes, the supernatant was removed and the cell pellet was gently 




 Matrigel matrix 
Melanoma cells  
embedded in 
Matrigel  
DMEM with 2% FBS 
+/-  factor X: 
•  Elesclomol 







Figure 8. 3D systems in vitro (1 single well). Melanoma cells are embedded within matrigel 
matrix. Such systems were supplemented with investigating factors dissolved in the 3rd soluble 
layer.  
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cell suspension. Paralelly, “blank” wells lacking tumor cells in the 2nd layer were 
prepared by adding 50 µl Matrigel solution on top of the polymerized 1st layer. 
Bobbles, if they appeared, were removed with a needle. After application, the plate 
was put into CO2 incubator at 37°C for at least 30 minutes to allow Matrigel 
polymerization.  
Finally, the polymerized gel was overlaid with 100µl of the 3rd top layer 
consisting of DMEM+2% FBS with or without investigated factor X (see Figure 8). 
All reagents and materials used in 3D Matrigel-based cell cultures are listed in 
Table 9. 
 
Table 9. Materials and instruments used in preparation of 3D Matrigel based models. 
Materials/Instruments: Company: 
96 well black walled-clear bottom plate Greiner bio-one, Germany 
1× DMEM Sigma Aldrich, Switzerland  
15, 50 ml tubes  Sarstedt, Nümbrecht 
Eppendorf tubes  Trefflab, Switzerland 
Inverse microscope Olympus IX81  Olympus, Norway  
BD Matrigel 
TM
 matrix BD Biosciences, USA 
Walac plate reader KSH-Productor Oy, Finland 
 
 
2.4.3 Treatment with Elesclomol in 3D 
 
To test cell sensitivity to therapy, Elesclomol was chosen as a drug. It is a 
new agent currently investigated for melanoma therapy at the Department of Tumor 
Biology. Melanoma cells were treated with various concentrations of Elesclomol.  A 
serial dilution of Elesclomol stock of 10mM was made to obtain the desired final 
concentrations of the drug in DMEM+2% FBS. 100µl of each concentration 
Elesclomol solution was added in the 3rd top layer of the 3D cultures. After 3 days cell 
viability was evaluated by the MTS method as described below. 
 
2.4.4 3D cultures supplemented with fibronectin and laminin  
 
To modify the 3D models with some additional components of ECM, two well 
known noncollageneous proteins i.e. fibronectin (derived from human fibroblasts) and 
laminin (derived from human placenta) were incorporated into the 2nd layer while 
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making the 3D cultures. Briefly, 1µl of fibronectin or laminin stock solutions 
(0.5mg/ml) was mixed into the 50µl of the 2nd layer solution (consisting of collagen 
and cells) to obtain a final concentration of the proteins in the 2nd layer 10µg/ml. The 
layer was allowed to polymerized and overlaid with 3rd layer as described previously 
(see Cell culturing in 3D). 
 
 
2.4.5 3D cultures supplemented with organ-conditioned medium  
 
 
Growing cells both in vitro and in vivo in an organism are known to secrete 
various soluble mediator substances, like T-growth factors and cytokines that may 
promote the growth of new cells. To describe media in which cells have been 
cultivated for a period of time, a term “conditioned media” (CM) is often used. Such 
media is cell-free, but is enriched with various soluble factors produced by the cells 
while the media and the cells were in contact. The same term can be used to 
describe media, which has been in contact with an organ for some time.  
In the present work, the conditioned media was prepared from brain, lungs, 
bone marrow and lymph nodes isolated from a healthy or a metastatic mouse 
(Figure 9). The mentioned organs represent commons sites of melanoma 
metastases, indicating that generally melanoma cells “like” to growth in the 




To prepare a conditioned media, each organ was cut by a scalpel into small 
pieces (~ 2 mm in size) that were transferred into a flask containing DMEM+2% FBS 
Brain Metastasis Healthy mouse 
Figure 9. Imaged mice. Healthy mouse and mouse with established Mel 1 metastasis in 
the brain which were used in CM preparations. 
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and incubated in 37ºC for 2 hours under constant agitation. For preparation of CM 
from brains and lungs, 2.5-3 ml of the medium was used for each organ. CMs from 
lymph nodes and bone marrow were prepared in the manner that organ-pieces were 
just covered with the medium (approximately 1.5 ml). After 2 hours of incubation, the 
conditioned medium was removed, filtrated through a 70µm filter for removal of the 
biggest tissue-pieces, and finally filtrated through 0, 22µm filter. The prepared CMs 
were stored at -80ºC in the freezer and thawed on ice when needed. 
For use in the experiments where the effect of CMs in 3D cultures was 
investigated, the conditioned media was diluted with DMEM+2% FBS in a ratio 
50:50. For one single well 50 µl of the CM was mixed with 50 µl of the growth media 
and added to the 3rd top layer of the collagen cultures.  
After evaluation of the results from the first experiments using CMs and based 
on the previously published data in the literature (Valle, Zalka et al. 1992; Cruz-
Munoz, Man et al. 2008), we decided to reduce the amount of CMs used. Further, 25 
µl of the organ-conditioned media was mixed with 75 µl DMEM+2% FBS (i.e. ratio 
25:75) and added to the 3rd top layer of the collagen matrixes. 
The 3D cell cultures supplemented with CMs were incubated at 37ºC for 4-5 
days before the effect was evaluated as described below (see Evaluation of 
growth/prolif and viability/metabolic activity: measurements methods).  
All reagents and materials used in preparations of organ-conditioned medium 
are listed in Table 10. 
 
 
Table 10. Materials and Instruments used in preparation of 3D cultures supplemented 
with organ-conditioned medium. 
Materials/Instruments: Company: 
1× DMEM Sigma Aldrich, Switzerland  
Fetal Bovine Serum (FBS) PAA, Austria 
Cell growth flasks with caps NUNC
TM
, Denmark 
Eppendorf tubes  Trefflab, Switzerland 




PBS Lonza, Belgium 
70μm filter BD Falcon
TM
, USA 
20µm filter CORNING®, Germany 
Syringes and needles Tamro, Finland 
Pincette Bastos Viegas, Portugal 
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2.4.6 3D cultures supplemented with organ-conditioned medium and 
treated with Elesclomol 
 
For use in the experiments where the effect of Elesclomol treatment in the 
presence of CMs in 3D cultures was investigated, the conditioned media was diluted 
with DMEM+2% FBS in a ratio either 50:50 or 25:75. Further, a serial dilution of 
Elesclomol stock of 10mM was made till the desired final concentrations of the drug 
by suing the medium containing the conditioned medium as indicate above. For one 
single well 100µl of each desired concentration of Elesclomol solution was added in 
the 3rd top layer of the 3D collagen cultures and cells were incubated for the desired 
time before analysis. 
 
 
2.5 Evaluation of cell viability and growth: measurement methods 
 
Several methods based on different principles have been used to evaluate 
general cell viability and cell functions like metabolic activity and growth/proliferation.  
To evaluate cell viability, we have used: 
• Staining with the “live” dye Calcein 
• Staining with the “dead” dye Propodium Iodide 
• Measurement of cells metabolic activity by the MTS method  
To evaluate cell growth/proliferation we have used: 
• DsRed-labeled cells and analyzed the DsRed signal intensity 
 
A short description of the mentioned methods is presented below.  
 
 
2.5.1 Cell viability measurement based on Calcein staining 
 
 
Calcein is a non-fluorescent compound which can be converted into the 
fluorescent polyanion calcein by cytosolic esterases in live cells. Therefore, Calcein 
fluorescence can be used as a measure of cell viability since viable cells fluoresce 
green. In the present work Calcein fluorescence was observed by microscopy and/or 
measured by a plate reader. Briefly, 50µl of PBS with 0, 25µl Calcein (stock 4 mg/ml) 
were added to a well with 3D cultures and incubated for 30 minutes at room 
temperature. Subsequently, the cells were observed by a fluorescence microscope 
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using a “FITC” filter (excitation at 450-490nm, emission at 515-565nm) or analyzed 
by a plate reader after excitation at 485nm and emission at 528nm. 
 
2.5.2 Staining with Propidium Iodide for visualization of dead cells 
 
 
Propidium Iodide (PI) is membrane impermeable and generally is excluded 
from viable cells. However, PI can enter dead cells where it binds to DNA or RNA so 
that the dead cells become stained. Therefore staining with PI can be used to 
visualize dead cells e.g. by microscopy.  For cell staining with PI, 2µl of PI stock 
solution (1 mg/ml) was added to a well containing 3D cultures and immediately 
observed by a microscope using a  “TRITC” filter (excitation at 550nm, emission at 
570nm). 
 
2.5.3 Evaluation of cells metabolic activity by the MTS assay  
(“Cell Titer 96®Aqueous Cell Proliferation Assay”) 
 
 
The MTS method is based on the reduction (by dehydrogenase enzymes) of 
the tetrazolium salt, MTS, to a colored formazan compound by metabolically active 
mitochondria in viable cells in culture. Metabolism in viable cells produces "reducing 
equivalents" such as NADH or NADPH. These reducing compounds pass their 
electrons to an intermediate electron transfer reagent that can reduce MTS into the 
formazan product, which is soluble in cell culture medium. Upon cell death, cells 
rapidly lose the ability to reduce MTS into formazan. The production of the colored 
formazan product, therefore, is proportional to the number of viable cells in culture. 
MTS stock solution from Promega was added directly to a well at a ratio of 
20μl MTS reagent to 100μl of culture medium in the top layer in 3D cultures or in 2D 
monolayers. Cells were incubated for 1–2 hours at 37°C, and then absorbance was 
measured at 490nm by a plate reader. Based on the absorption data the viability was 
calculated. The viability/metabolic activity data were presented either as % relative to 
controls, or as Absorbance at 490nm. 
 
 
2.5.4 Evaluation of cell growth/proliferation by measuring intensity of 
the DsRed signal 
  
 
In the experiments where the DsRed-labeled cells were used, cell 
growth/proliferation was evaluated by monitoring a DsRed fluorescence intensity by a 
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plate reader. This method is “noninvasive” i.e. cells stay unaffected and therefore can 
be analyzed repeatedly measuring the fluorescence in the same wells over time. 
Briefly, the DsRed-labeled Melmet cells were embedded in 3D matrix in black-walled 
clear-bottom 96 wells plates (see Figure 10) as described above in “General 3D 
culturing.” The black walls allowed to avoid fluoresce “leakage” to the neighboring 
wells during the measurements of the DsRed signal. The DsRed signal intensity was 
followed over time, usually up to 5 days after the initiation of the experiment. 
Measurements of the DsRed signal intensity was performed by a Synergy 2 plate 
reader (excitation at 530nm).  
 
 
Figure 10. Schematic presentation of measurement of intensity of a DsRed signal. The 
DsRed labeled cells cultured in 3D (right) in black-well plates (left) were analyzed by  a plate 
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3.1 Evaluation of melanoma cell growth and viability in 3D cultures  
 
 
To grow the cells in 3D in the presence of ECM components, Collagen is 
usually used as a matrix. Another often used matrix is Matrigel, which is generally 
richer in growth factors compared to collagen and therefore can be suitable for cells 
that do not grow well in collagen. However, Matrigel is also much more expensive 
and therefore, collagen is often the first choice in studies based on 3D cultures.  
 The aim of this part of the work was to find the conditions suitable for culturing 
of Melmet cells in 3D matrixes. For this, we have tested collagen I, Matrigel, the 
presence/absence of serum, different cell amounts, and followed Melmet cell growth 
and/or viability by various approaches. Specifically, we have measured: a) the 
DSRed signal intensity to reveal the increase in the number of DSRed-labeled 
Melmet cells (= cell growth); b) cells metabolic activity by the MTS method to reveal 
cell viability and/or grow; c) visualized live and dead cells by microscopy after 
staining of cell cultures with the “live and dead” dyes Calcein and Propidium Iodide. 
The choice of the method varied depending on the specific experiment.  
 We have started the study from Melmet 5 since this cell line is easy to work 
with, the cells grow fast and we knew from the previous studies that these cells can 
grow in collagen matrixes. 
 
3.1.1 Optimization of culturing conditions for Melmet 5 in collagen 




The following parameters have been investigated first: 1) amount of Melmet 
cells seeded in a well; 2) presence/absence of serum (FBS) in a growth medium in a 
3rd (top) layer of the 3D cultures. In these studies DSRed-labeled Melmet 5 cells were 
used, and the DSRed signal was measured.  
First, a correlation between a cell number and DsRed fluorescence was 
evaluated. The DSRed signal for three different concentrations of cells (20.000/-, 
60.000/- and 120.000/well) was measured after 24 hours of culturing. Cells were 
grown in 3D collagen matrix in the medium without serum, with 2% serum and with 
10% serum.  
As shown in the Figure 11, the DsRed signal intensity was higher for the 
higher amount of cells seeded, indicating that the signal intensity was proportional to 
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the cell number. This also indicated that measurements of the increase of the DsRed 
signal can be used to follow the increase in cell number, which indicates cell growth.  
 


















    
Figur 11. DSRed signal for three different concentrations of Mel5 DSRed cells in 3D 
cultures containing media of different compositions. “-“= wells containing RPMI++ 
medium without serum; “2%FBS” = wells containing the medium with 2 % serum; “10% FBS” 
= wells containing the medium with 10% serum. Relative Fluorescence Units (RFU) of the 
DSRed signal are shown on the Y axis, and the medium compositions are indicated on the X 
axis.  
 
Under the conditions with 2% serum a slightly higher DsRed signal was 
registered for the two highest cell concentrations (see Figure 11). Although the 
difference was not significant, it suggested that the presence of 2% serum was 
beneficial for the cells. Serum promotes cell growth and/or survival, which might 
result in higher cell amounts and thus, higher DsRed fluorescence compared to the 
conditions without serum.  
 
           
Figure 12. Visualization of the viable (i.e. green) Melmet 5 DSRed cells grown in DMEM 
medium with (left) or without (right) 2% serum in the 3rd layer of the 3D cultures. The 
cells were cultured for 4 days and stained with the “live dye” Calcein to identify the viable cells 
(pictures taken using 4x objective). 
DMEM +2% FBS DMEM 
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The later experiments supported this observation, and as can be seen in 
Figure 12, there was a higher amount of viable (i.e. green) cells in 3D cultures 
containing 2% serum compared to the serum-free cultures. 
It should be noted that the intensity of the DsRed signal in cultures with 10% 
serum was reduced for all cell concentrations tested (Figure 11). Generally, 10% is a 
widely accepted serum concentration for cell culturing in vitro, which however might 
be not optimal for our experiments where the fluorescence has to be measured, 
since the presence of serum can interfere with the fluorescence measurements. 
To investigate further cell growth in 3D over time in the presence versus 
absence of serum, we have followed the increase in DsRed signal for up to 5 days. 
Melmet 5 DSRed cells were cultured in 3D collagen using the medium with 2% 
serum or the serum-free medium in the 3rd layer. The DSRed signal was measured 
after 24, 96 and 120 hours of culturing.  
As we can see in Figure 13, Melmet 5 cells were able to growth even under 
the conditions without serum where they doubled their number on day 5 compared to 
day 1. Under the conditions with 2% serum, the DsRed signal on day 5 was 
increased significantly more, approximately 5-fold compared to day 1. Likewise, on 
day 4 it was also observed a higher DsRed signal in serum-containing compared to 
serum-free medium. This confirms that the medium with 2% serum is beneficial for 
growing Melmet 5 cells for several days.  




















Figure 13. Melmet 5 cells growth during 5 days of culturing in 3D collagen matrixes. 
60000 DSRed Melmet 5 cells were seeded in the 2nd layer of collagen matrixes as described 
in Material and Methods. The growth medium in the 3rd layer was either DMEM or DMEM+2 
% FBS as indicated on the X axis;  On days 1, 4 and 5 (indicating respectively 24, 96 and 120 
hours after the initiation of the experiment) the DsRed signal was measured. Fold increase in 
the DsRed signal relative to the signal on day 1 is shown on the Y axis.  
 
Summarizing, it seems that for Melmet 5 the collagen matrix and the medium 
with 2% serum might represent the suitable conditions for culturing in 3D. Also, 
60000 cells/well seem to be a suitable cell concentration since this cell amount gave 
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easy-detectable (clearly above the background) fluorescence signals. Therefore, 
these conditions have been use for the majority of the subsequent experiments with 
Melmet 5. 
 
3.1.2 Evaluation of Melmet 1 growth in 3D matrixes 
 
Based on the results above, we have attempted to use similar culturing 
conditions also for Melmet 1 cells. However, we increased cell number to 100.000 
cells/well, since Melmet 1 generally grows much slowed and gives lower DsRed 
signals compared to Melmet 5 (data not shown). Melmet 1 cells were seeded in 3D 
collagen matrix in the medium with 2 % serum in the 3rd layer. The visual inspection 
by the microscope of the similar cultures with Melmet 1 raised doubts to whether 
these cells were viable and growing suggesting that Melmet 1 cells might not like to 
be cultured under these conditions – the cells were round, dark and did not look 
viable (data not shown). Therefore, we decided to control if Melmet 1 cells are still 
viable and are proliferating during culturing for 4 days in a collagen matrix and 
instead of measuring the DsRed signal, we have measured cells metabolic activity by 
the MTS method, which is an accepted approach for evaluation of cell viability. The 
MTS assay was performed after 1, 3 and 4 days of culturing. Paralelly, the cells were 
also stained with live/dead dyes Calcein/PI at the same time points. It has to be 
noticed that cells were seeded on three different plates so that MTS-measurements 
and staining procedures at the early time points could not affect the growth of the 
cells that were analyzed at the later time points.  
As we can see in Figure 14 A, the metabolic activity of Melmet 1 cells was 
reduced approximately 2-fold after 4 days of culturing in collagen, indicating that only 
~ 50 % of the cells remained viable. Figure 14 B compares the MTS signal 
measured in the well with collagen without cells (=collagen background) and wells 
with cells in collagen, revealing that the signal “produced” by viable cells was only 1.4 
fold above the background. This is not much having in mind that this system was 
planed to be used for therapy studies, where decrease in cell number (consequently 





Figure 14. Metabolic activity (viability) of Melmet 1 during culturing in 3D collagen 
matrixes. Melmet 1 cells (100000 cells/well) were seeded in the 2nd layer of collagen. A: 
Cells metabolic activity was measured by the MTS method on days 1, 3 and 4 (indicating 
respectively 24, 72 and 96 hours after the initiation of the experiment) and are presented as 
% relative to day 1 and are indicated on the Y axis. B: Absorbance signal measured at 490nm 
(raw data) in cell-free collagen (“collagen” indicates a background signal) and collagen with 
Melmet 1 cells (“Mel 1 cells”) on day 3. Absorbance signal is indicated on the Y axis.  
 
Figure 15 confirms that the amount of viable (green) Melmet 1 cells in 
collagen on days 3 and 4 were reduced significantly compared to day 1; 
consequently, the amount of dead (red) cells was increased. Thus, pictures taken 
after 3 days of culturing shows us a lot of red cells, even though green cells are still 
in the majority, while after 4 days, the red cells are dominating. To note, some very 
few red cells are seen already after 24 hours of culturing in 3D collagen. It should be 
added that the ratios between green and red cells observable by the microscope 
varied depending on the area where the pictures were taken. Despite this variation, 
based on the results shown in Figures 14 and 15 it can be concluded that on day 3, 
10% and more of the cells are already dead and on day 4 this number reaches at 
least 50%, suggesting that the decline in cell viability of Melmet 1 started already 
after 2 days of incubation in collagen. 
 
 
Figure 15.  Evaluation of Melmet 1 viability in 3D collagen cultures. Visualization of cells 
stained with live/dead dyes Calcein/PI on days 1, 3 and 4 (pictures of the same area are 
taken using 10X objective and respective filters for Calcein (green) and PI (red) and 
subsequently combined). 






































To test whether Matrigel could be used instead of collagen for culturing of 
Melmet 1 cells, we performed a pilot experiment, where the cells were seeded in 
Matrigel in the medium with 2% FBS in the 3rd layer as described in Materials and 
Methods (see “Cell culturing in 3D: Matrigel cultures”). The cultures were inspected 
by microscopy, and cells metabolic activity was measured by the MTS method after 3 
days of culturing.  
Based on the microscopic evaluation we concluded that the cells looked 
“nicer” compared to the collagen cultures (data not shown). The MTS measurements 
revealed that the MTS signal detected in the wells with Matrigel+cells compared to 
the wells with only Matrigel was 1.7-fold higher (Figure 16). This indicates that the 
MTS signal produced by the viable cell was slightly higher in the Matrigel-based 
culture (Figure 16) compared to the collagen-based culture (Fig. 14B).  
 
 





















Figure 16. MTS signal intensity in Melmet 1 cultures in in Matrigel. Melmet 1 cells 
(100000 cells/well) were seeded in the 2nd layer of Matrigel matrix. Paralelly, a cell-free well 
containing only Matrigel in the 2nd layer was prepared for comparison. On day 3 (indicating 72 
hours after the initiation of the experiment) the MTS signal was measured in the wells 
containing only Matrigel” or Matrigel with cells (“Mel1 cells”) indicated on the X axis. The MTS 
absorbance data are presented on the Y axis.  
 
Based on these experiments we concluded that Matrigel might be a more 
suitable matrix than collagen for culturing of Melmet 1 in 3D. Therefore, most of the 
subsequent studies with Melmet 1 were performed in Matrigel. However, it can be 
mentioned that one additional experiment using Melmet 1 and collagen 
supplemented with additional proteins form extracellular matrix was performed as 
described in the next section (see 3.2.3 Evaluation of the effect of the ECM proteins 




3.2 Investigation of the effect of extracellular matrix (ECM) proteins 
 
Cell adhesion to the extracellular matrix (ECM) plays a major role in cellular 
communication and regulates a variety of cellular processes including proliferation, 
survival and motility. As discussed in the introduction, tumour cells can interact with 
various proteins of ECM, and these interactions might influence tumour cell growth 
and viability. Therefore, in the present part of the work we investigated how the 
selected proteins of ECM influence melanoma cell growth and viability. The focus 
was on Melmet 5, since Melmet 5 was more suitable for culturing in 3D collagen-
based matrixes.  
 
 
3.2.1 Evaluation of Melmet cell adhesion to various ECM proteins 
 
 
To map the ECM proteins that the Melmet cells could adhere to, we have 
employed ECM arrays containing the most important proteins of ECM: collagens I, II, 
and IV, fibronectin, laminin, tenascin and vitronectin. Figure 17 reveals the ability of 
Melmet cells to adhere to these proteins. 
 
Figure 17. Cell adhesion to ECM components array profiles. A: Melmet 5. B: Melmet 1.  






















































































































































































As can be seen Melmet 1 and Melmet 5 had different tendency regarding 
adhesion to selected ECM proteins (Figure 17 A. 1 and 2). Melmet 1 adhered almost 
equally efficiently to all investigated proteins, while Melmet 5 (see Figure 17 B. 1 and 
2) was adhering very poorly to collagen IV and vitronectin, suggesting that Melmet 5 
has low levels of these respective receptors. 
 It has to be noticed that it has been performed two independent biological 
experiments for each cell line using cells at different passage numbers. This explains 
some variations in the absolute numbers shown on axis Y in Figure 17. Despite this 
variation, it can be easily seen the same tendency regarding adhesion to selected 
proteins of ECM in both experiments for each cell line.  To note, collagen I (the main 
component of collagen-matrix) and laminin (the main component of Matrigel-matrix) 
were among the proteins both Melmet cell lines adhered efficiently to.   
 
 
3.2.2 Evaluation of the effect of the ECM proteins fibronectin and 
laminin: Melmet 5 
 
 
Mapping of the adherence to various ECM proteins revealed that both Melmet 
1 and Melmet 5 was efficiently binding to fibronectin (FN) and laminin (LN) and 
indicated that Melmet cells posses the receptors assuring binding to these two 
proteins. Therefore, it was of interest for us to explore whether the presence of these 
two proteins in 3D cultures affected growth of Melmet cells. 
Fibronectin and laminin represent the ECM proteins that have been shown 
previously by others to be associated with metastasis (see Introduction section). 
First, we have focused on Melmet 5. 3D cultures were supplemented with these ECM 
proteins by adding Fibronectin or Laminin (at a final concentration 10µg/ml) to the 2nd 
collagen layer together with the DsRed-labeled Mel 5 cells as described in Materials 
and Methods (see section “3D cultures supplemented with fibronectin and laminin”). 
In the 3rd layer, the medium with or without 2% serum was used. Cell growth was 
followed for up to 4 days by measuring the DS Red signal. At the end of the 
experiment i.e. on day 4, all cultures were stained with the Calcein dye to quantify 
and visualize the viable cells. As can be seen in Figure 18, the DsRed signal on day 
4 was increased approximately 1.5-2 fold compared to day 1, indicating an increase 




































Figure 18. Melmet 5 cell growth in 3D collagen matrix in the presence or absence of 
fibronectin. 60000 DSRed Melmet cells were seeded in the 2nd collagen layer with or without 
10µg/ml fibronectin (FN, indicated on the X axis) as described in Material and Methods. The 
growth mediums used in the 3rd layer where DMEM or DMEM+2%FBS. The DsRed signal 
was measured on days 1, 3 and 4 which corresponds to respectively 24, 72 and 96 hours 
after the initiation of the experiment. Fold increase relative to day 1 is shown on the Y axis. 
Errors bars indicate StDv from 2 parallels.  
 
However, FN did not show a significant influence on cell proliferation or 
viability, since the intensity of both the DSRed and the Calcein signal were the same 
in the presence and absence of FN (Figure 19 A).  
 
 
Figure 19. Evaluation of fibronectin effect on the viability of Melmet 5: staining with 
Calcein. Cells were cultured in 3D with or without 10µg/ml FN in the 2nd layer as 
described in the Figure 18 text. At the end of the experiment i.e. on day 4, the 3D cultures 
were stained by adding 0.25 µl Calcein as indicated in Materials and Methods. A: Green 
Calcein signal was measured by a plate reader Synergy 2 and Relative Fluorescence Units 
(RFU) are shown on the Y axis; media compositions in the 3rd layer are indicated on the X 
axis; error bars indicate StDv from 2 parallels. B: Viazualization of viable Calcein-stained cells 
by microscopy (pictures taken using 4x objective; the compositions in the 3rd layer and the 
presence of FN is indicated in the figure). 
 
 
Furthermore, Figure 19 B illustrates that there was no visual difference in the 
amount of viable (green) cells in the presence versus absence of fibronectin. 
DMEM+2%FBS+ FN 

















However, Figure 19 B confirms that the amount of viable cells was higher when the 
medium with 2% serum was used compared to serum-free medium. This 
corresponds to the earlier observation (see Figure 12). 
Similar experiments were performed to evaluate an effect of laminin on 
growth and viability of Melmet 5. As can be seen in Figure 20, laminin also did not 
stimulate cell growth significantly since the DsRED signal intensity in the presence 



































Figure 20. Melmet 5 cell growth in 3D collagen matrix in the presence or absence of 
laminin. 60000 DSRed Melmet cells were seeded in the 2nd collagen layer with or without 
10µg/ml laminin (LN, indicated on the X axis) as described in Material and Methods. The 
growth mediums used in the 3rd layer were either DMEM or DMEM+2%FBS. The DsRed 
signal was measured on days 1, 3 and 4 which corresponds to respectively 24, 72 and 96 
hours after the initiation of the experiment. Fold increase relative to day 1 is shown on the Y 
axis. Errors bars indicate StDv from 2 parallels.  














Figure 21. Measurement of Calcein signal on day 4. DMEM=wells containing DMEM in the 
top layer of 3D cultures; DMEM+2%FBS=DMEM supplemented with 2% serum in the top 
layer of 3D cultures; cells=wells containing cells; cells+LN=wells containing cells and 1µl 
Laminin embedded in the 2nd layer. Relative Fluorescence Units (RFU) is shown on the Y axis 
and media compositions on X axis. Error bars indicate StDv of 2 parallels. 
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However, measurements of the Calcein signal (Figure 21) suggested that cell 
viability could be slightly higher in cultures with LN compared to the cultures lacking 
LN, and this was more pronounced in cultures with 2% serum.  
Therefore, we decided to investigate the potential effect of the ECM proteins 
on cell viability more closely by measuring cells metabolic activity. Thus, Melmet 5 
cells were seeded in a collagen matrix supplemented with laminin or fibronectin as 
described above and after 4 days cells metabolic activity was measured by the MTS 
method. This time we could not see any difference between the cells grown in the 
presence of laminin or fibronectin versus the cells grown without these proteins 
(Figure 22).  


















Figure 22. Melmet 5 cell metabolic activity in 3D collagen matrix in the presence or 
absence of laminin and fibronectin. 60000 Melmet 5 cells were seeded in the 2nd collagen 
layer with or without 10µg/ml FN and 10µg/ml LN (indicated on the X axis) as described in 
Material and Methods. The growth medium used in the 3rd layer was DMEM+2%FBS.The 
MTS absorbance signal (indicated on Y axis) was measured after 4 days which corresponds 
to 96 hours after the initiation of the experiment. Errors bars indicate StDv from 2 parallels. 
 
Figure 23. Evaluation of Melmet 5 viability in 3D collagen cultures supplemented with 
FN and LN. Combined picture (top) illustrating cells stained with live/dead dyes Calcein/ 
Propidium Iodide on day 4 and Phase contrast picture (bottom) of the same area. (Pictures 






Also Figure 23, showing the viable and dead cells after staining of the 
cultures with Calcein/PI, indicates approximately equal amounts of green (viable) and 
red (dead) cells in the presence or absence of fibronectin and laminin. 
Altogether, this indicates that we could not confirm by the MTS and the 
Calcein/PI staining methods that laminin or fibronectin has an effect on the viability of 
Melmet 5 grown in collagen.   
 
 
3.2.3 Evaluation of the effect of the ECM proteins fibronectin and 
laminin: Melmet 1 in collagen matrix 
  
Previously we have shown that Melmet 1 did not “like” to be cultured in 
collagen matrix using the conditions suitable for Melmet 5. However, assuming that 
fibronectin and laminin might have an effect on cell viability (see the data and the 
discussion above), we have performed a similar study on Melmet 1 and investigate 
whether addition of these proteins to collagen cultures could improve the 
growth/viability of Melmet 1. Thus we have cultured Melmet 1 cells in less dense 
collagen (1.5mg/ml instead of traditional 2.5mg/ml) supplemented with 10 µg/ml 
fibronectin or laminin. After 4 days cells metabolic activity and viability were 
evaluated by the MTS and Calcein/PI methods.  
As can be seen in Figures 24 and 25, neither fibronectin nor laminin had a 
notable effect.  























Figure 24. Melmet 1 cell metabolic activity in 3D less-dense collagen matrix (1, 5 mg/ml) 
in the presence or absence of laminin and fibronectin. 60000 Melmet 5 cells were seeded 
in the 2nd collagen layer with or without 10µg/ml FN and 10µg/ml LN (indicated on the X axis) 
as described in Material and Methods. The growth medium used in the 3rd layer was 
DMEM+2%FBS.The MTS absorbance signal (indicated on Y axis) was measured after 4 days 
which corresponds to 96 hours after the initiation of the experiment. Errors bars indicate StDv 
from 2 parallels. 
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However, it might seem from Figure 25 that red (dead) cells are not 
dominating like it was the case in more-dense collagen cultures (see Figure 23 
above).  
Summarizing, we conclude that fibronectin and laminin did not have a notable 





Figure 25. Evaluation of Melmet 1 viability in 3D collagen (1,5 mg/ml) cultures 
supplemented with FN and LN in the 2nd layer. Visualization of cells stained with live/dead 




3.3 Effect of organ-conditioned medium 
 
To evaluate whether Melmet cells can be influenced by soluble factors 
released from the organs – common sites of melanoma metastasis – 3D cultures 
were supplemented with organ-conditioned medium (CM). Also here we focused on 
Melmet 5 cells. CMs were prepared from brain, lungs, bone marrow and lymph nodes 
of healthy mice as described in Materials and Methods, diluted 50:50 with fresh 
medium containing 2 % FBS and applied to the 3rd layer of the 3D cell cultures.  In 
control wells, the medium with 2% serum without CM was applied to the 3D cell 
cultures. Cultures were grown for up to 5 days and the results were analyzed by 
measuring cells metabolic activity by the MTS method on days 3 and 5 (Figures 26-
27). In addition, cells growth pattern was analyzed by microscopy (Figures 28-29).  
 
 
DMEM + FN + LN 
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Figure 26. Metabolic activity of Melmet 5 cells incubated for 3 days in the presence of 
CM from A: Brain and Lungs; B: Bone Marrow (BM) and Lymph Nodes. CMs were 
diluted with DMEM+2% serum at a ratio 50:50 and added as a 3rd layer to the 3D cultures 
containing 60000 Melmet 5 cells as indicated in Materials and Methods. In control wells, 
DMEM+2% serum without CM was used. Cells metabolic activity was evaluated by the MTS 




As shown in Figure 26, none of the investigated CM affected cells metabolic 




Figure 27. Metabolic activity of Melmet 5 cells incubated for 5 days in the presence of 
CM from A: Brain and Lungs; B: Bone Marrow (BM) and Lymph Nodes. CMs were 
diluted with [DMEM+2% serum] at a ratio 50:50 and added as a 3rd layer to the 3D cultures 
containing 60000 Melmet 5 cells as indicated in Materials and Methods. In control wells, 
DMEM+2% serum without CM was used. Cells metabolic activity was evaluated by the MTS 
method and is presented as absorbance on the Y axis. Error bars indicate StDv from 2 
parallels. 
 
However, it might seem that organ-derived cells released from bone marrow- 
and lymph node-conditioned media stimulate the survival and proliferation of Melmet 


























































































soluble factors stimulating growth of melanoma cells in collagen matrix (Figure 27 
B). 
Interestingly, microscopic observation of the cultures revealed that the 
conditioned media from brain and lungs had an effect on cells growth pattern and 
morphology inducing the formation of complex structures (“rings” and “chains” 
(Figure 28) compared to the cells incubated only with the medium +2% FBS, where 
mostly separated single cells were observed.  
 
 
Figure 28. Growth pattern of Melmet 5 cells incubated with CM from lungs and brain. 
Phase contrast pictures were taken on day 5 using 20X (left) and 32x (right) objectives. CMs 
were diluted with the medium DMEM+2 % serum at a ratio 50:50. For comparison cells were 












Furthermore, the conditioned media from bone marrow induced even more 
complex cell structures, and these structures looked more like clumps of elongated 
cells (Figure 29). Also the conditioned media from lymph nodes stimulated the 
formation of elongated complex cell structures as shown in (Figure 29).  
 
 
Figure 29. Growth pattern of Melmet 5 cells incubated with CM from bone marrow and 
lymph nodes. Phase contrast pictures were taken on day 3 using 20x (left); 40x (right) 
objectives. CMs were diluted with the medium DMEM+2 % serum at a ratio 50:50. For 
comparison cells were cultured in the medium DMEM+2 % serum without CM. 
 
 
It has been published previously that too high amount of the CM might 
actually inhibit cell growth (Valle, Zalka et al. 1992). Therefore, we have performed a 
similar experiment but reduced the amount of CM added to 25 % instead of 50%. 












medium at ratio 25:75 and added to the 3rd layer of the 3D cell cultures. Cell 
metabolic activity was evaluated after 5 days by the MTS method.  
In contrast to the previous experiment where 50% of CM was used (see 
Figures 26 A and 27 A), here the CM from the lungs and brain seem also to 
stimulate the cells (Figure 30) .As can be seen in Figure 30, a ~1, 5-fold increase in 
relation to DMEM+2%FBS was observed . CM from bone marrow and lymph nodes 
also showed a stimulating effect on the cells.  
 
 





















Figure 30. Effect of CM from brain, lungs bone marrow (BM) and lymph nodes on 
metabolic activity of Melmet 5. CMs were diluted with the medium [DMEM with 2% serum] 
at a ratio 25:75 and added as a 3rd layer to the 3D cultures containing 60000 Melmet 5 cells. 
In control wells, DMEM with 2% serum without CM was added to the cell cultures. Metabolic 
activity was evaluated by the MTS method and is presented on the Y axis as fold increase 




To evaluate the effect of CM on Melmet 1, the cells were embedded in the 2nd 
Matrigel layer which was overlaid with CM diluted with the medium at a ration 25:75. 
3D cultures were incubated for 4 days and cell metabolic activity was measured by 
the MTS method. 
As we can see in Figure 31, all investigating CMs had more or less 
stimulating effect on the Melmet 1 cell, however, it should be noted that the standard 























Figure 31. Incubation of Melmet 1 cells for 4 days in the presence of CM from brain, 
lungs bone marrow (BM) and lymph nodes. CMs were diluted with DMEM medium 
supplemented with 2% serum at a ratio 25:75 and added as a 3rd layer to the 3D Matrigel 
cultures containing 60000 Melmet 1 cells as indicated in Materials and Methods. In control 
wells, DMEM+2% FBS without CM was used. Cells metabolic activity was evaluated by the 
MTS method and is presented as fold-increase relative to DMEM+2% FBS on the Y axis. 
Error bars indicate StDv from 2 parallels. 
 
Further we wanted to investigate whether CM prepared from a metastatic 
mouse will have a different effect on Melmet cells compared with CM from a healthy 
mouse. It is known that a growing tumour and its microenvironment might lead to 
secretion of various soluble factors (particularly those promoting tumour growth) 
different from normal conditions. Therefore, it was of interest to investigate how 
Melmet cells respond to soluble factors extracted from a mouse with metastases. We 
used only Melmet 5 cells for these studies. Thus, CM prepared from brain, lungs, 
lymph nodes and BM of a metastatic mouse was diluted with the medium DMEM+2 
% FBS at a ratio 25:75 and added to the 3rd layer of 3D cell cultures. For comparison, 
we used CM prepared from a healthy mouse diluted at the same ratio 25:75. Cell 
metabolic activity was measured on the last day of incubation i.e. at day 5.  
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Figure 32. Incubation of Melmet 5 cells for 5 days in the presence of CM from brain, 
lungs, bone marrow and lymph nodes of metastatic and healthy mouse. CMs were 
diluted with DMEM+ 2% serum at a ratio 25:75 and added as a 3rd layer to the 3D collagen 
cultures containing 60000 Melmet 5 cells as indicated in Materials and Methods. In control 
wells, DMEM+ 2% FBS without CM was used. Cells metabolic activity was evaluated by the 




As we can see in Figure 32, all CM seems to have a stimulating effect 
compared to the medium without CM. Interestingly, CM obtained from the lymph 
nodes, bone marrow and maybe lungs seems to stimulate cells to a greater extent 
than CM obtained from the same organs of a healthy mouse, however the difference 
was not big and not statistically significant.  
 
 
3.4 Therapy-related studies 
 
 
To investigate how the sensitivity of melanoma cells to drugs can be 
modulated by TME factors, we have measured cell viability after treatment with the 
drug Elesclomol. Elesclomol is a new ROS-inducing agent currently investigated on 
preclinical melanoma models at the Department of Tumour biology, where this 




3.4.1 Effect of Elesclomol on Melmet 5 in 2D and 3D cultures  
 
It is known that tumour cell sensitivity to drugs can differ when cells are 
treated in 2D versus 3D cultures (discussed in the Introduction). To compare 
Elesclomol effect on Melmet 5 cell viability in 3D and 2D cultures, we have tested 
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different concentrations of the drug: 2nM, 10nM, 50nM, 200nM, 1000nM and 2000nM 
(see Materials and Methods, “Elesclomol as factor X”). 
For 3D experiments, 60.000 Melmet 5 cells/well were seeded in collagen 
matrix; Elesclomol at the mentioned concentrations was added to the 3rd (top) layer 
and the cultures were incubated for 3 days.  
To evaluate Elesclomol effect on Melmet 5 in 2D cultures, 10000cells/well 
were seeded in the medium as described previously in Materials and Methods. The 
next day, the growth medium was replaced with the new medium containing 
Elesclomol at different dilutions and incubated for 3 days. Cell viability in both 3D and 
2D cultures was measured after 3 days (72 hours) of the treatment by the MTS 
method. 
 As we can be seen in Figure 33, the viability of the cells was reduced with 
increasing concentration of the drug in both cultures.  
In 2D cultures, we achieved complete response using 2000nM of Elesclomol. 
This is supported by microscopic visualization (see Figure 34), were we could not 
observe any viable cells after the treatment with 2000nM of the drug. Also when 
1000nM of Elesclomol was used, the viability of the cells was significantly reduced 
reaching approximately only 35% (Figure 33 “2D”).  
 



















Figure 33. Viability of Melmet 5 cells in 2D and 3D following treatment with different 
consentrations of Elesklomol: 2nM, 10nM, 20nM, 50nM, 200nM, 1000nM and 2000nM. 
3D: Cells (60000/well) were embedded in the collagen matrix. 2D: Cells (10000/well) were 
seeded in RPMI++ on the day 0 and the next day the medium was replaced with the medium 
containing Elesclomol. Elesclomol was added at indicated concentrations in the 3rd (top) layer 
of the 3D cultures or to 2D monolayer’s on day 1 as described in Materials and methods. Cell 
viability was measured by the MTS method and is presented as percentage of untreated 
controls on the Y axis; used concentrations of the drug are indicated logarithmic on the X 




The microscopy pictures in Figure 34 confirm that while most of the cells are 
dead/dying (rounded cells) we could still see some viable cells when 1000nM 
Elesclomol was used in 2D. The smallest concentrations of the drug used, 10nM 




Figure 34. Cell visualization following the treatment of Melmet 5 cells with Elesclomol 
in 2D. Elesclomol concentrations used are indicated in the figure. Phase contrast pictures 
were taken using a 10X objective. 
 
 
In 3D cultures, cell viability was reduced to approximately 60% after treatment 
with 2000nM Elesclomol, which induced complete toxicity in 2D (see Figure 33 
“3D”). The low concentrations of the drug (2nM, 10nM, 50nM) did not have any 
inhibitory effect in 3D cultures. 
These data support the previous observations that cells are more sensitive to 
the drug in 2D culture compared to cells grown in 3D matrixes supporting the theory 
that there is a difference between these two systems with respect to drug-response.  
 
 
3.4.2 Effect of organ-conditioned medium on Melmet 5 sensitivity to 
Elesclomol in 3D 
 
Further we wanted to investigate if organ-conditioned medium (CM) has an 
effect on the viability of Melmet 5 cells treated with Elesclomol. Besides, we wanted 
to evaluate whether CM prepared from a metastatic mouse and CM prepared from a 
healthy mouse can induce different effects. For these studies we have used CMs 
prepared from the brains. 
Melmet 5 cells were embedded in the 2nd collagen layer. Elesclomol was 
diluted to 2000nM with the medium consisting of CM and DMEM +2% FBS at a ratio 
10000cells/well 
0nM 1000nM 2000nM 
Viable cells 
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25:75. The drug solution was added to the 3rd layer, and the MTS assay was 
performed after 3 days (i.e. 72 hours) of the treatment.  
As can be seen in Figure 35, the treatment reduced cell viability to 
approximately 50-60% corresponding to the previous results obtained in 3D (see 
Figure 33). Unfortunately, we could not observe any significant effect of CM: 
although the cells treated in the presence of CM showed slightly higher sensitivity to 
the drug, the differences were not statistically significant. Furthermore, there was no 
significant difference between treatments in the presence of CM from the metastatic 
mouse compared to the CM from the healthy mouse.   
 


















Figure 35. Effect of brain-CM from metastatic mouse versus healthy mouse on viability 
of Melmet 5 cells following treatment with Elesklomol. Melmet 5 cells (60000/well) were 
embedded in the 3D collagen matrix. Elesclomol (2000nM ) was added to the growth medium 
in the 3rd (top) layer with or without CM from a metastatic or healthy brain; “control” = wells 
without Elesclomol; “2000nM E-mol” =concentration of Elesclomol is 2000nM per well; Cell 
viability was measured by the MTS method and is presented on the Y axis as percentage 
relative to untreated controls; used concentrations of the drug are indicated on the X axis. 




3.4.3 Effect of Elesclomol on Melmet 1 in 2D and 3D cultures 
 
To evaluate the effect of the therapy with Elesclomol on Melmet 1 cells, the 
studies in 2D were performed first. Since Melmet 1 are significantly bigger and grow 
significantly slower compared to Melmet 5, two cell densities were tested: 5000- and 
10000 cells/well. Elesclomol serially diluted to different concentrations with the 
medium with 2 % FBS was added to the cells, and cell viability was measured on day 
3 (i.e. after 72 hours) of treatment by the MTS method. 
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As can be seen in Figure 36, cells sensitivity to Elesclomol was dependent 
on cell density. For 5000cells/well, inhibitory effect of Elesclomol “starts” when the 
drug concentrations exceed 10nM, and the viability declines to ~40% when 
Elesclomol concentration reaches 20nM. At 50nM only ~10% of the cells are alive. 
This effect of Elesclomol is supported by the microscopy-studies shown in Figure 37 
(left panel), where we can see that very few cells stay viable at Elesclomol 
concentration of 50nM. When 200nM Elesclomol was used, there were no viable 
cells left (Figure 36) in the wells were 5000 cells were seeded. 
 
 



















Figure 36. Viability of Melmet 1 cells in 2D following treatment with Elesklomol. Cells 
(5000/well and 10000/well) were seeded in 2D cultures as described in Materials and 
Methods. Elesclomol was diluted with the growth medium to 10nM, 20nM, 50nM, 200nM, 
1000nM and 2000nM (as indicated on X axis, logarithmic scale) and added to the cells. Cell 
viability was measured by the MTS method and is presented as percentage of untreated 
controls on the Y axis. 
 
 
On the contrary, for wells with more cells i.e. 10000 cells/well, the decline in 
viability starts at higher Elesclomol concentration i.e. exceeding 20nM, and cell 
viability goes down to ~70% at Elesclomol concentration of 50nM (see Figure 36). 
Also Figure 37 (right panel) indicates that there are left viable cells at Elesclomol 
concentration of 50nM. When cells were treated with 1000nM, the viability of the cells 
was reduced to approximately 10% (Figure 36), which was also confirmed by the 
microscopic inspection indicating the presence of some but very few viable cells (see 
Figure 37 right panel).  
Furthermore, this experiment has shown that 1000nM of Elesclomol is almost 





Figure 37. Cell visualization following the treatment of Melmet 1 cells with Elesclomol 
in 2D. 5000 cells (left panel) and 10000 (right panel) cells were treated with Elesclomol at the 
concentrations indicated on the figure. Phase contrast pictures taken using 10X objective. 
 
 
To confirm that Melmet 1 is more sensitive to Elesclomol than Melmet 5 in 2D 
independently on cell density, we have seeded 10000 cells of Melmet 1 and 2x less 
(5000 cells) of Melmet 5 and treated them with 200nM Elesclomol for 3 days before 
microscopic inspection. As can be seen in Figure 38, 200nM Elesclomol had hardly 
any effect on Melmet 5 (the cells looked elongated and nice); while more than half of 












Figure 38. Cell visualization following the treatment (200nM Elesclomol) of 10000 
Melmet 1 and 5000 Melmet  5 cells/well. Phase contrast pictures taken using 10X objective. 
 
 
Further, the Elesclomol effect on Melmet 1 in 3D Matrigel-cultures was 
evaluated. The cells were embedded in the 2nd Matrigel layer and overplayed with 
Elesclomol serially diluted to concentrations: 50nM, 200nM, 1000nM and 2000nM.  
The MTS assay was performed after 3 days (i.e. 72 hours) of the treatment. 
As can be seen in Figure 39, in 3D almost full effect of the treatment was 
achieved with the Elesclomol concentration of 2000nM, and ~ 40% of the cells were 
still viable following the treatment with 1000nM.  
 
 






















Figure 39. Comparison of Melmet 1 cell viability in 3D versus 2D following treatment 
with different concentrations of Elesclomol: 2nM, 10nM, 20nM, 50nM, 200nM, 1000nM 
and 2000nM. For 3D, cells (60000/well) were embedded in the 2nd layer of Matrigel matrix. 
Elesclomol was added at indicated concentrations in the 3rd layer. 2D cultures were prepared 
using 5000cells/well as described in Figure 33. Cell viability was measured by the MTS 
method and is presented as percentage of untreated controls (on the Y axis); used 
concentrations of the drug are indicated on the X axis (logaritmic scale). Error bars for 3D 
data indicate StDv from 2 parallels.  
 
Mel 5: 5000cells/well 
200nM 
Mel 1: 10000cells/well 
200nM 
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These results indicate that also Melmet 1 is less sensitive to the treatment in 
3D than in 2D (compare blue versus pink line in Figure 39). Furthermore, 
comparison of the 3D data shown in Figure 39 and Figure 33 confirms that Melmet 1 
is more sensitive to Elesclomol treatment compared to Melmet 5 also in 3D since we 




3.4.4 Effect of organ-conditioned medium on Melmet 1 sensitivity to 
Elesclomol in 3D 
 
Further, we investigated if brain-conditioned medium has an effect on viability 
of Melmet 1 cells treated with Elesclomol. The cells were embedded in the 2nd 
Matrigel layer. Elesclomol was diluted to 1000nM with the medium consisting of CM 
and DMEM+2% FBS at a ratio 25:75 and, added to the 3rd layer. The MTS assay was 
performed after 3 days (i.e. 72 hours) of the treatment.  
As shown in Figure 40, 1000nM Elesclomol reduced cell viability to 20-40%, 
corresponding to the previous results shown in Figure 39. Interestingly, we could 
observe ~10% stimulating effect of CM on the viability of the treated Melmet 1 cells 
compared to the cells treated in the absence of CM. However, the difference was 
very small and needs further investigation before final conclusions.  


















Figure 40. Effect of brain-CM from a healthy mouse on viability of Melmet 1 cells 
following treatment with 1000nM Elesklomol in 3D. Cells (60000/well) were embedded in 
the 3D Matrigel, and Elesclomol was added to the 3rd layer with or without CM from the brain; 
”untreated” = wells without Elesclomol; “1000nM E-mol”=concentration of Elesclomol is 
1000nM per well; Cell viability was measured by the MTS method and is presented in 
percentage relative to untreated controls (on the Y axis); used concentrations of the drug are 







In the present work three-dimensional (3D) extracellular matrix-based cell 
cultures were employed to study in vitro whether and how various factors of tumor 
microenvironment modulate melanoma cell properties, specifically 
growth/proliferation and sensitivity to therapy.  
 
Although 3D cultures mimic the body’s conditions much better than traditional 
2D cultures, generally 3D systems are NOT widely used models for in vitro studies, 
because they are much more difficult to make and to work with. Therefore, a big part 
of the present work was related to search of “optimal” conditions for culturing and 
analysis of Melmet cells in 3D. This explains why different analysis methods (i.e. 
measurement of DsRed fluorescence, Calcein signal, MTS signal and microscopic 
evaluation) have been used along the project to evaluate the behavior of melanoma 
cells in 3D. We were looking for culturing conditions and cell amounts that would lead 
to an easy measurable signal allowing to follow cell viability and growth. Furthermore, 
this signal had to be significantly above the background level, since this was 
necessary for therapy-studies where a decrease in cell-associated signal was 
expected as a result of cell killing by a drug. Thus, screening of several cell 
concentrations revealed that 60-100 thousand cells per well in a 96-well plate fulfill 
the above mentioned criteria. Initially we wanted to omit serum in our 3D cultures, 
since serum might interfere with fluorescence/absorbance measurements that our 
analysis methods were based on. However, comparison of cell growth and viability in 
serum-free versus serum-containing cultures revealed that the presence of serum 
was important for the cell state and therefore, we have chosen to supplemented the 
3D cultures with low concentration (2%) of serum in the majority of the experiments. 
Also we have observed that while Melmet 5 grew well in a matrix of collagen 
I, Melmet 1 did not do so. There could be several reasons for that. One of the 
possibilities could be lack of respective receptors for interaction with collagen I. 
However, our study where adhesion of Melmet cells to ECM proteins was evaluated 
revealed that Melmet 1 interacts efficiently well with all investigated proteins, 
including collagen I. Another possibility which was considered was related to the 
density of collagen matrix where the cells were embedded. It could be that the used 
concentration of collagen i.e. 2.5mg/ml formed too dense matrix for Melmet 1 cells, 
which are much larger in size compared to Melmet 5 growing well in 2.5mg/ml 
collagen. Indeed, we have observed that culturing of Melmet 1 in less dense collagen 
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(1.5mg/ml) seems to result in fewer dead cells than in dense collagen (see Figure 15 
“day 3” and Figure 25 “DMEM”). This suggests that theoretically it might be possible 
to find more suitable conditions for culturing of Melmet 1 in collagen-based 3D. 
However, based on our observation that Melmet 1 cells looked “nicer” in Matrigel 
matrix than in collagen, we have chosen to focus on Matrigel instead of optimizing 
collagen conditions for Melmet 1.  
Eventually, based on the said above, for Melmet 5, we have chosen to use 
collagen I matrix, 60000 cells/well and the medium with 2% serum in the 3rd (top) 
layer of 3D cultures. For Melmet 1 - Matrigel matrix, 100000 cells/well and the same 
medium with 2% serum were chosen as satisfactory conditions. Under these 
conditions the measured signal associated with the cells was significantly above the 
background level and thus: a) easy measurable; b) suitable for therapy-studies where 
a decrease in cell-associated signal was expected as a result of a drug effect. 
 
Trying to bring the 3D models even closer to in vivo condition, we have 
supplemented them with additional components of ECM, fibronectin and laminin - two 
important proteins known to be linked to metastasis (discussed in the Introduction). 
The aim was to investigate whether the presence of these proteins modulate growth 
and viability of Melmet cells. It has been shown by Kaplan et al. that elevation of 
fibronectin level may be associated with the formation of a pre-metastatic niche, as 
described in the Introduction (Kaplan, Riba et al. 2005). Furthermore, it has been 
shown that transition from a dormant (i.e. non-proliferative) state to a proliferative 
state in breast cancer cells was dependent on fibronectin production (Barkan, 
Kleinman et al. 2008), and such transition must occur during metastasis formation in 
order to give macrometastases. Altogether this suggests that fibronectin might be a 
fundamental component in establishing a favorable microenvironment for tumor cell 
growth, proliferation and survival leading to metastases (Barkan, Green et al.). In our 
systems though, neither fibronectin nor laminin modulated notably growth and/or 
survival of Melmet cells. The lack of effect can not be explained by the lack of 
respective receptors on the surface of Melmet cells. Thus, our data on adhesion to 
ECM (Figure 17) indicated that both Melmet 1 and Melmet 5 could efficiently bind to 
these proteins. Generally, Melmet 1 demonstrated an efficient binding to all 7 ECM 
proteins that were investigated, while Melmet 5 lacked the ability to bind efficiently to 
collagen IV, vitronectin and tenescin. Altogether, our data does not exclude a 
possibility that fibronectin and laminin might have an effect under different conditions. 
However, here we conclude that under investigated conditions – when 10μg/ml of the 
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proteins was added to the 2nd layer of collagen containing cells – fibronectin and 
laminin did not affect significantly the cells properties that were analyzed.  
 
To investigate how various soluble factors might affect melanoma cell growth 
and viability, we have supplemented 3D cultures with conditioned media (CM) 
prepared from various organs isolated from experimental animals. Mouse brain, 
lungs, bone/bone marrow and lymph nodes were used. These organs are known to 
represent common sites of melanoma metastases, indicating that melanoma cells 
like to grow in their microenvironments. When such CMs were added to the 3D 
cultures, we have observed a slight stimulatory effect on cell growth/viability. 
Although the stimulatory effect was not big i.e. did not exceed 2-fold, it was confirmed 
in several independent experiments in both Melmet lines. Interestingly, the effect was 
observed when the CMs were diluted with fresh medium at a ratio 25:75, and not at 
50:50, indicating that the CM effect depends on the optimal (i.e. lower) concentration 
of CM. This corresponds to the earlier publications that also demonstrated that high 
concentration of CM might be not optimal and might even inhibit cell growth (Valle, 
Zalka et al. 1992; Cruz-Munoz, Man et al. 2008). The fact that CMs from all 4 organs 
induced quite similar effect (shown in Figures 30 and 31) might suggest that the 
effect was associated with the factors e.g. growth factors generally present in the 
organs i.e. in vivo. To note, Melmet 5 is known to be able to establish metastases in 
experimental animals in brain, lungs, bone marrow and lymph node (Prasmickaite 
et.al, manuscript in preparation), ant therefore the fact that Melmet 5 cells can 
respond to CM from these organs is not very surprising.  
Further, we have observed that CM had a very clear effect on morphology 
and growth pattern in Melmet 5 – the cells formed more complex elongated 
structures. This effect was especially pronounced for CM from bone marrow and 
lymph nodes. The result that bone marrow factors affect tumor cells corresponds well 
to the recently proposed role of bone marrow-derived cells (BMDC) in the metastasis 
process. As discussed in the introduction, BMDC seem to be strongly involved in 
metastasis via the formation of a “pre-metastatic niche” (Kaplan, Riba et al. 2005) i.e. 
BMDC are recruited to metastatic sites to induce changes that stimulate growth of 
tumor cells. This suggests that BMDC might secrete factors required for stimulation 
of tumor growth, and therefore conditioned media from bone marrow might be rich in 
these factors. The significance of cell morphology changes induced by the CM from 
bone marrow (as well as from other organs) has not been investigated further in the 
present work. However, the observation that in the presence of CM  tumour cells 
 66
“communicate” more forming complex structures/clumps instead of single separated 
cells is interesting and worth further investigation.  
In addition, we have tested an effect of conditioned media prepared from a 
metastatic mouse. The idea behind this experiment was that the growing tumour i.e. 
metastases might induce the production of soluble factors that further stimulate tumor 
growth. Therefore, we speculated that CM from a metastatic mouse might have a 
more pronounced effect on tumor cell growth than the CM from a healthy mouse. 
However, our results indicated that although CM from a metastatic mouse had a 
small stimulatory effect on Melmet 5 growth, the difference was not significant 
compared to CM from a healthy mouse. It should be noted that this experiment was 
not optimally performed. First, the metastatic mouse had metastases only in the 
brain, and not in other investigated organs (Figure 9 in Materials & Methods). 
Therefore it is probably not surprising that we could not detect a significant difference 
between the CM from “metastatic” compared to CM from healthy mouse lungs, bone 
marrow and lymph nodes. Secondly, the metastases formed in the brain were small 
i.e. contained relatively few tumor cells. Therefore, it can be that microenvironmental 
changes (e.g. secretion of soluble factors) induced by such small metastases are not 
strongly pronounced and are not very significant. Thus, this experiment should be 
repeated by preparing CM from a mouse with clearly detectable metastases not only 
in the brain, but also in other investigated organs.  
  
A big part of the present project was devoted to therapy-related studies. The 
original idea was to use 3D cultures for evaluation of the effect of the new promising 
anti-melanoma drug PLX 4032 discussed in the Introduction. PLX targets mutated 
BRAF, and both Melmet 1 and Melmet 5 have this mutation (Prasmickaite, 
unpublished). Unfortunately, the delivery of this drug was delayed by the 
manufacturer, so that the drug was not available for the present project. Instead, we 
have used another drug, Elesclomol, which is proposed for melanoma therapy and is 
currently in clinical trials. Evaluation of Elesclomol efficiency in 2D in various 
melanoma cell lines (not Melmets) is ongoing in the Department of Tumour Biology, 
and therefore it was of great interest to evaluate Elesclomol in Melmet cell lines, 
particularly in 3D cultures. Evaluation of the Elesclomol effect in 2D versus 3D 
revealed that in both cell lines Elesclomol induced a stronger effect in 2D, indicating 
that cells growing in 2D were more sensitive to the drug. This correspond to the 
published data on other cell lines and other drugs (Smalley, Lioni et al. 2006; 
Serebriiskii, Castello-Cros et al. 2008) and supports the theory that there is a 
difference between 2D and 3D systems with respect to drug-response. This also 
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signifies the importance of performing preclinical tests of new drugs or drug 
combinations in 3D systems.  
Although the sensitivity of Melmet 1 to Elesclomol in 2D was dependent on 
cell number/density, the general observation was that Melmet 1 was more sensitive 
than Melmet 5 both in 2D and 3D systems. Thus, in 3D cell viability was reduced by 
50% when Elesclomol concentration exceeded 500nM for Melmet 1 and 2000nM for 
Melmet 5, indicating at least 4-fold difference in sensitivity between these cell lines. 
We have not investigated further the reasons for such difference. It might be that 
Melmet 1 and Melmet 5 have different levels of intracellular ROS. The action 
mechanism of Elesclomol is based on the elevation of the ROS levels above the 
“threshold”, which is toxic for a cell. It might be that cells that are more sensitive to 
Elesclomol, like Melmet 1, also have higher levels of intracellular ROS.  
Further, we have investigated, whether conditioned media from the brains 
might influence the response to Elesclomol.  We hypothesized that soluble factors 
present in these organs might protect the tumor cells, increasing their viability and 
therefore reducing drug-effect. The idea was based on the fact that melanoma 
metastases are usually highly refractory to therapies. Unfortunately, our hypothesis 
was not supported by the experimental results. The only experiment that was 
performed indicated a slightly lower viability (i.e. better Elesclomol effect) when CM 
was used, and these data were not verified further.  
Summarizing, this work was the initial evaluation on how various factors from 
tumor microenvironment affect malignant melanoma cells in 3D cultures in vitro.  The 
established conditions and the obtained results put a basis for further studies on 
tumor-microenvironment interactions in malignant melanoma by using 3D matrix-















• The conditions suitable for culturing of Melmet cells in 3D matrixes for 
up to 5 days have been established. These include: for Melmet 1- 
Matrigel matrix; for Melmet 5 - 2.5mg/ml collagen I matrix. The growth 
medium in the top layer of 3D cultures has to be supplemented with at 
least 2% serum. 
• Cell adhesion to 7 proteins of ECM has been evaluated. Both Melmets 
adhered efficiently to laminin and fibronectin. Melmet 1 could 
efficiently bind to all other investigated proteins, while Melmet 5 
showed low/no binding to collagen IV, tenascin and vitronectin.  
• The presence of laminin and fibronectin in 3D cultures did not affect 
Melmet cell growth and/or viability. 
• The conditioned media i.e. soluble factors extracted from brain, lungs, 
bone marrow and lymph node of experimental mice showed a slight 
stimulating effect on Melmet cell growth, and notable effect on cell 
morphology and growth pattern, particularly in the case of the media 
conditioned with bone marrow.   
• Both Melmet cell lines demonstrated higher sensitivity to the drug 
Elesclomol in 2D than in 3D, and Melmet 1 cells were more sensitive 
than Melmet 5. The brain-conditioned media did not increase the 
























• More optimal culturing conditions for Melmet 1 in 3D remains to be 
found. Although we concluded here that Matrigel is an acceptable 
matrix for Melmet 1, generally the 3D culturing conditions for Melmet 1 
were only satisfactory, but not very good. Further optimization, like 
changing concentration of the collagen (less dense matrixes) and 
varying cell number as well as supplementation with some additional 
TME factors may improve the quality of Melmet 1 3D cultures. 
• An effect that organ-conditioned medium seem to have on morphology 
and growth pattern of Melmet 5 cells has not been investigated further 
in the present work, but is definitely an interesting observation which is 
worth further investigation, furthermore, in both cell lines.  
• Further investigation of the effects of conditioned medium from 
metastatic organs compared to “healthy” organs remains to be 
performed. Preparation of CM from a more “optimal” mouse with 
notable metastases in multiple organs should be tested in the future.  
• Therapy-related studies in 3D, testing e.g. the most promising anti-
melanoma drug PLX4032 in the presence or absence of TME factors, 
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